MedTrace Logo

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2007-12-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Samarium Sm-153 lexidronam + Docetaxel

1 mCi/kg Sm153 + 75 mg/m2 docetaxel

Sponsors & Collaborators

  • Cytogen Corporation

    lead INDUSTRY

Principal Investigators

  • Michael J Morris, M.D. · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00121095 on ClinicalTrials.gov